Paulo Teixeira shines a light on Pfizer’s promising pipeline for 2018, the market access environment in Portugal and the clinical trial landscape. Teixeira intends to contribute to improving society’s perception of the pharmaceutical industry and position Pfizer as a partner for health and wellbeing in Portugal; part of the solution—not the problem, in ensuring the sustainability of the healthcare system.
What are your priorities for this year?
"Overall, Portugal is well positioned, and our critical concern is to deliver innovation to patients in need in our country. With an incredibly promising pipeline, we can be very confident to continue to succeed in the future."
